Public Health

Morisky Medication Adherence Scale-8 (MMAS-8): A Full Guide for Researchers and Clinicians

0.0

0.0 out of 5 stars (based on 0 reviews)

Introduction

Medication non-adherence is a significant barrier to effective chronic disease management, impacting patient outcomes and healthcare costs. Consequently, reliable tools to assess adherence are critical for clinicians and researchers. The Morisky Medication Adherence Scale-8 (MMAS-8), developed by Donald E. Morisky in 2008, and published by MMAR, LLC dba ADHERENCE, is a widely used, validated instrument for evaluating medication adherence in patients with chronic conditions such as hypertension and diabetes. With over 4,000 citations on Google Scholar, the MMAS-8 has established itself as a cornerstone in health behavior research (Morisky et al., 2008).

This article provides a comprehensive guide for experts, detailing the MMAS-8’s features, applications, and value in clinical and research settings.

Key Features of the Morisky Medication Adherence Scale-8 (MMAS-8)

Purpose and Use

The MMAS-8 assesses medication adherence in patients with chronic conditions, focusing on both intentional and unintentional non-adherence. Specifically, it helps clinicians identify barriers to adherence and supports researchers in studying treatment effectiveness. Moreover, its concise design makes it ideal for busy clinical environments and large-scale studies.

Target Population

The MMAS-8 targets adults aged 18 and older, including young adults (18–24), middle-aged adults (25–44), older adults (45–64), and seniors (65+). Specifically, it is designed for patients with chronic diseases such as hypertension, diabetes, and asthma, making it highly relevant for chronic care settings.

Structure

The MMAS-8 comprises 8 questions covering various aspects of medication adherence:

Item 1: Forgetfulness (unintentional non-adherence)
Item 2: Recent unintentional non-adherence (not due to forgetfulness)
Item 3: Intentional non-adherence when feeling worse
Item 4: Travel-related forgetfulness
Item 5: Recent adherence (reverse-coded)
Item 6: Intentional non-adherence when feeling better
Item 7: Burden of medication regimens
Item 8: Frequency of forgetfulness

Items 1–7 use yes/no responses, while Item 8 employs a 5-point Likert scale (never to always), ensuring a nuanced assessment of adherence behaviors.

Administration Format

The MMAS-8 takes less than 5 minutes to administer, making it highly efficient. It can be conducted via:

Paper-based forms
Digital (Online) platforms
In-person (Interview)
Phone/Video call

Its self-administered format, requiring no specialized training, enhances its practicality for busy clinical environments.

Applications of Morisky Medication Adherence Scale-8 (MMAS-8)

The MMAS-8 offers significant value in clinical and research settings:

Screening: Identifies patients with low adherence to medications.
Diagnosis: Supports assessment of adherence-related issues in chronic disease management.
Monitoring: Tracks adherence over time, particularly during treatment adjustments.
Treatment Planning: Informs strategies to improve patient adherence.
Research: Widely used in studies evaluating interventions for chronic disease management.

For example, clinicians can use the MMAS-8 to identify barriers to adherence in diabetic patients, while researchers can assess the impact of adherence on clinical outcomes

Languages and Availability

To support global use, the MMAS-8 is available in over 30 languages, including:

Arabic
English
Mandarin Chinese
Spanish
French
Russian
German
Portuguese
Japanese
Hindi
As well as more than 30 languages.

This extensive multilingual availability enhances its applicability in diverse clinical and research context.

The MMAS-8 is a copyrighted instrument under a proprietary license. Permission from MMAR, LLC dba Adherence is required for its use in clinical or research settings. Researchers and clinicians must contact MMAR, LLC to obtain a license, ensuring compliance with copyright laws.

Reliability and Validity

The MMAS-8 is recognized as a highly reliable and valid instrument for assessing medication adherence. Its psychometric strength is demonstrated by a Cronbach’s alpha of 0.83, indicating good internal consistency. Additionally, it shows strong test-retest reliability, ensuring stability over time.

Validation Study:

- Original Validation Study
- Type 2 Diabetes Validation

Limitations and Considerations

However, despite its strengths, the MMAS-8 has a few limitations:

Self-report: Patients may underreport non-adherence due to social desirability bias.
Cultural Bias: May require adaptations for optimal use in certain cultural contexts.
Narrow Focus: Focuses solely on medication adherence, missing broader health behavior factors.
Age Restrictions: Not suitable for patients under 18, requiring alternative tools for younger populations.

These limitations suggest that clinicians and researchers should complement the MMAS-8 with objective adherence measures or culturally tailored tools when necessary.

Additional Resources

For more information on the MMAS-8 and to access the full questionnaire, visit the following resources:

Download the MMAS-8 Questionnaire (PDF)
Official Source
For inquiries, contact MMAR, LLC dba Adherence.
For additional MMAS-8 resources, consult www.moriskyscale.com.

Frequently Asked Questions (FAQ)

Who can use the MMAS-8?
Clinicians and researchers use the MMAS-8 for adults aged 18+ with chronic conditions like hypertension or diabetes.
How long does it take to complete the MMAS-8?
Patients typically take less than 5 minutes to complete the MMAS-8, making it efficient for clinical use.
How is the MMAS-8 administered?
The MMAS-8 can be administered via paper-based, digital (online), in-person interview, or phone/video call formats, offering flexibility.
Is there any cost to using the MMAS-8?
The MMAS-8 requires permission from MMAR, LLC for use, as it is a copyrighted instrument.

A word from ResRef about Morisky Medication Adherence Scale-8 (MMAS-8)

The Morisky Medication Adherence Scale-8 (MMAS-8) is a validated, self-report questionnaire designed to assess medication adherence in patients with chronic conditions. The MMAS-8 has demonstrated acceptable internal consistency and reliability across various chronic conditions, including hypertension, diabetes, and asthma. Its validity has been confirmed in multiple languages and cultural contexts, making it a versatile tool for both clinical practice and research. It’s important to note that the MMAS-8 is a copyrighted instrument, and proper licensing is required for its use in clinical or research settings.

References

Morisky, D. E., Ang, A., Krousel-Wood, M., & Ward, H. J. (2008). Predictive validity of a medication adherence measure in an outpatient setting. The Journal of Clinical Hypertension, 10(5), 348–354. (link)
Martinez-Perez, P., Orozco-Beltrán, D., Pomares-Gomez, F., Hernández-Rizo, J. L., Borras-Gallen, A., Gil-Guillen, V. F., Quesada, J. A., Lopez-Pineda, A., & Carratala-Munuera, C. (2021). Validation and psychometric properties of the 8-item Morisky Medication Adherence Scale (MMAS-8) in type 2 diabetes patients in Spain. Atención Primaria, 53(2), 101942. (link)